BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36112929)

  • 21. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
    Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
    Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Establishment and Clinical Significance of Prognostic Nomogram Model for Diffuse Large B-Cell Lymphoma Based on Immunohistochemistry Markers and International Prognostic Index Scores].
    Xu YW; Zhou YL; Kong FC; Chen ZW; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):753-761. PubMed ID: 37356936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
    Na HY; Choe JY; Shin SA; Kim HJ; Han JH; Kim HK; Oh SH; Kim JE
    PLoS One; 2019; 14(10):e0224247. PubMed ID: 31644584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].
    Zhan J; Yang SJ; Zhang W; Zhou DB; Zhang Y; Wang W; Wei C
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):41-47. PubMed ID: 35231992
    [No Abstract]   [Full Text] [Related]  

  • 26. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 27. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 28.
    Hu B; Nastoupil LJ; Loghavi S; Westin JR; Thakral B; Fayad LE; Hagemeister F; Neelapu S; Samaniego F; Lee HJ; Wang ML; Fanale M; Fowler N; Oki Y
    Leuk Lymphoma; 2020 Feb; 61(2):328-336. PubMed ID: 31533521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in de novo CD5+ diffuse large B cell lymphoma.
    Jain P; Fayad LE; Rosenwald A; Young KH; O'Brien S
    Am J Hematol; 2013 Sep; 88(9):798-802. PubMed ID: 23695956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
    Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
    Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD5+ diffuse large B-cell lymphoma: a narrative review.
    Durani U; Ansell SM
    Leuk Lymphoma; 2021 Dec; 62(13):3078-3086. PubMed ID: 34284686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
    Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
    Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
    Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.
    Fan Y; Binshen O; Zhang Z; Yi H; Zhang W; Liu Q; Liu Y; Dong L; Wang C
    Ann Diagn Pathol; 2022 Jun; 58():151886. PubMed ID: 35255429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities.
    Kano R; Masaie H; Hino A; Yasuoka H; Nagata S; Ishikawa J; Nakatsuka SI
    Diagn Pathol; 2018 Jul; 13(1):46. PubMed ID: 30041681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of MCP-1 and CCR2 in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Clinical Significance].
    Wang M; Zhang PP; Zhu Q; Hu ZL; Bai X; Wu YP; Li JJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):112-119. PubMed ID: 38387908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
    Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
    Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.